Reata Pharmaceuticals, Inc. (RETA) financial statements (2021 and earlier)

Company profile

Business Address 5320 LEGACY DRIVE
PLANO, TX 75024
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments818578610624664240280
Cash and cash equivalents818578610624664240280
Receivables22222222   
Other undisclosed current assets7785567
Total current assets:847607640652669247287
Noncurrent Assets
Property, plant and equipment5544333
Other noncurrent assets5188101010
Total noncurrent assets:1061212131313
TOTAL ASSETS:858613652664682259300
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19272833262325
Accounts payable591113244
Accrued liabilities14181720242021
Deferred revenue5555531 
Debt   335 
Contract with customer, liability31
Other liabilities22151514121411
Other undisclosed current liabilities73  147147  
Total current liabilities:11947472011927568
Noncurrent Liabilities
Long-term debt and lease obligation21516216275 
Long-term debt, excluding current maturities   15615575 
Operating lease, liability21567  
Liabilities, other than long-term debt6491112177186
Deferred revenue 1245171 
Contract with customer, liability179
Other liabilities6377768
Other undisclosed noncurrent liabilities3133763596260 80
Total noncurrent liabilities:321380374235234252266
Total liabilities:440427421436426327334
Stockholders' equity
Stockholders' equity attributable to parent, including:417186232229257(67)(33)
Additional paid in capital1,3761,0781,059988967456450
Accumulated deficit(958)(892)(827)(759)(710)(524)(484)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:417186232229257(67)(33)
TOTAL LIABILITIES AND EQUITY:858613652664682259300

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:3131388
Operating expenses(57)(56)(54)(69)(187)(47)(41)
Operating loss:(54)(54)(51)(67)(184)(39)(34)
Nonoperating expense(12)(11)(17)(4)(3)(1)(1)
Investment income, nonoperating0012112
Interest and debt expense (2)(11)(6)(4)(2)(2)
Loss from continuing operations before equity method investments, income taxes:(66)(67)(79)(77)(191)(42)(37)
Other undisclosed income from continuing operations before income taxes 2116422
Loss from continuing operations before income taxes:(66)(66)(68)(71)(187)(40)(34)
Income tax expense (benefit)000220(0)(0)
Net loss available to common stockholders, diluted:(66)(65)(68)(49)(187)(40)(34)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(66)(65)(68)(49)(187)(40)(34)
Comprehensive loss, net of tax, attributable to parent:(66)(65)(68)(49)(187)(40)(34)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: